Ignite Creation Date:
2024-05-06 @ 8:09 PM
Last Modification Date:
2024-10-26 @ 3:21 PM
Study NCT ID:
NCT06270602
Status:
RECRUITING
Last Update Posted:
2024-02-21
First Post:
2024-01-29
Brief Title:
The ONCOCAMP Study
Sponsor:
National Cancer Institute Naples
Organization:
National Cancer Institute Naples
Study Overview
Official Title:
A Retrospective-prospective Observational Multicentric Study to Record Data From the ROC Platform and Monitor the ROC Performance
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The present study is a retrospective-prospective observational and multicentric study aiming to collect data relating to all patients included in the ROC platform All ROC centers will be involved in the present study
Detailed Description:
The ROC platform therefore represents a multicenter database and a growing source of data and information regarding cancer patients in the Campania region The need for multicenter databases is supported by the results obtained with both retrospective and prospective studies Many retrospective studies have led to changes in some of the available guidelines Important advantages of this study include representativeness of the analyzed cohort to all patients with a specific cancer and a large sample size that provides sufficient statistical power to detect differences across different patient groups The data extracted from the ROC have the potential to produce knowledge to guide decision-making and to manage more effectively the challenges of fighting cancer in our region The Campania region counts more than 6 million people and it is characterized by a worst oncological outcome compared to the average data of other Italian region the ROC platform has the potential to analyze the effect of a public intervention in the field of oncology care Therefore the primary aim of this study is to create a retrospective-prospective registry of all cancer patients entering the ROC platform and in a GOM path describing the primary and secondary endpoints
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 623 oss | OTHER | IRCCS INT G Pascale | None |